Read by QxMD icon Read


shared collection
541 papers 100 to 500 followers
By César Gerardo Martínez Hernández General and Nuclear Cardiologist
Stuart J Connolly, Mark Crowther, John W Eikelboom, C Michael Gibson, John T Curnutte, John H Lawrence, Patrick Yue, Michele D Bronson, Genmin Lu, Pamela B Conley, Peter Verhamme, Jeannot Schmidt, Saskia Middeldorp, Alexander T Cohen, Jan Beyer-Westendorf, Pierre Albaladejo, Jose Lopez-Sendon, Andrew M Demchuk, Daniel J Pallin, Mauricio Concha, Shelly Goodman, Janet Leeds, Sonia Souza, Deborah M Siegal, Elena Zotova, Brandi Meeks, Sadia Ahmad, Juliet Nakamya, Truman J Milling
BACKGROUND: Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors. METHODS: We evaluated 352 patients who had acute major bleeding within 18 hours after administration of a factor Xa inhibitor. The patients received a bolus of andexanet, followed by a 2-hour infusion. The coprimary outcomes were the percent change in anti-factor Xa activity after andexanet treatment and the percentage of patients with excellent or good hemostatic efficacy at 12 hours after the end of the infusion, with hemostatic efficacy adjudicated on the basis of prespecified criteria...
February 7, 2019: New England Journal of Medicine
Francis J Alenghat, Andrew M Davis
No abstract text is available yet for this article.
February 4, 2019: JAMA: the Journal of the American Medical Association
Scott D Solomon, Adel R Rizkala, Martin P Lefkowitz, Victor C Shi, JianJian Gong, Nagesh Anavekar, Stefan D Anker, Juan L Arango, Jose L Arenas, Dan Atar, Turia Ben-Gal, Sergey A Boytsov, Chen-Huan Chen, Vijay K Chopra, John Cleland, Josep Comin-Colet, Hans-Dirk Duengen, Luis E Echeverría Correa, Gerasimos Filippatos, Andreas J Flammer, Michel Galinier, Armando Godoy, Eva Goncalvesova, Stefan Janssens, Tzvetana Katova, Lars Køber, Małgorzata Lelonek, Gerard Linssen, Lars H Lund, Eileen O'Meara, Béla Merkely, Davor Milicic, Byung-Hee Oh, Sergio V Perrone, Naresh Ranjith, Yoshihiko Saito, Jose F Saraiva, Sanjiv Shah, Petar M Seferovic, Michele Senni, Antonio S Sibulo, David Sim, Nancy K Sweitzer, Jyrki Taurio, Dragos Vinereanu, Bojan Vrtovec, Jiří Widimský, Mehmet B Yilmaz, Jingmin Zhou, Robert Zweiker, Inder S Anand, Junbo Ge, Carolyn S P Lam, Aldo P Maggioni, Felipe Martinez, Milton Packer, Marc A Pfeffer, Burkert Pieske, Margaret M Redfield, Jean L Rouleau, Dirk J Van Veldhuisen, Faiez Zannad, Michael R Zile, John J V McMurray
BACKGROUND: To describe the baseline characteristics of patients with heart failure and preserved left ventricular ejection fraction enrolled in the PARAGON-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in HFpEF) comparing sacubitril/valsartan to valsartan in reducing morbidity and mortality. METHODS AND RESULTS: We report key demographic, clinical, and laboratory findings, and baseline therapies, of 4822 patients randomized in PARAGON-HF, grouped by factors that influence criteria for study inclusion...
July 2018: Circulation. Heart Failure
Uffe Ravnskov, Michel de Lorgeril, David M Diamond, Rokuro Hama, Tomohito Hamazaki, Björn Hammarskjöld, Niamh Hynes, Malcolm Kendrick, Peter H Langsjoen, Luca Mascitelli, Kilmer S McCully, Harumi Okuyama, Paul J Rosch, Tore Schersten, Sherif Sultan, Ralf Sundberg
For half a century, a high level of total cholesterol (TC) or low-density lipoprotein cholesterol (LDL-C) has been considered to be the major cause of atherosclerosis and cardiovascular disease (CVD), and statin treatment has been widely promoted for cardiovascular prevention. However, there is an increasing understanding that the mechanisms are more complicated and that statin treatment, in particular when used as primary prevention, is of doubtful benefit. Areas covered: The authors of three large reviews recently published by statin advocates have attempted to validate the current dogma...
October 2018: Expert Review of Clinical Pharmacology
Craig T January, L Samuel Wann, Hugh Calkins, Lin Y Chen, Joaquin E Cigarroa, Joseph C Cleveland, Patrick T Ellinor, Michael D Ezekowitz, Michael E Field, Karen L Furie, Paul A Heidenreich, Katherine T Murray, Julie B Shea, Cynthia M Tracy, Clyde W Yancy
No abstract text is available yet for this article.
January 21, 2019: Journal of the American College of Cardiology
Craig T January, L Samuel Wann, Hugh Calkins, Lin Y Chen, Joaquin E Cigarroa, Joseph C Cleveland, Patrick T Ellinor, Michael D Ezekowitz, Michael E Field, Karen L Furie, Paul A Heidenreich, Katherine T Murray, Julie B Shea, Cynthia M Tracy, Clyde W Yancy
No abstract text is available yet for this article.
January 28, 2019: Circulation
Amalia Peix, Ganesan Karthikeyan, Teresa Massardo, Mani Kalaivani, Chetan Patel, Luz M Pabon, Amelia Jiménez-Heffernan, Erick Alexanderson, Sadaf Butt, Alka Kumar, Victor Marin, Claudio T Mesquita, Olga Morozova, Diana Paez, Ernest V Garcia
BACKGROUND: Placing the left ventricular (LV) lead in a viable segment with the latest mechanical activation (vSOLA) may be associated with optimal cardiac resynchronization therapy (CRT) response. We assessed the role of gated SPECT myocardial perfusion imaging (gSPECT MPI) in predicting clinical outcomes at 6 months in patients submitted to CRT. METHODS: Ten centers from 8 countries enrolled 195 consecutive patients. All underwent gSPECT MPI before and 6 months after CRT...
January 25, 2019: Journal of Nuclear Cardiology: Official Publication of the American Society of Nuclear Cardiology
Konstantinos Dimopoulos, Robin Condliffe, Robert M R Tulloh, Paul Clift, Rafael Alonso-Gonzalez, Radwa Bedair, Natali A Y Chung, Gerry Coghlan, Samantha Fitzsimmons, Alessandra Frigiola, Luke S Howard, Petra Jenkins, Damien Kenny, Wei Li, Simon T MacDonald, Colm McCabe, James J Oliver, Mark S Spence, Gergely V Szantho, Kate von Klemperer, Dirk G Wilson, Stephen J Wort
Echocardiography is the mainstay in screening for pulmonary hypertension (PH). International guidelines suggest echocardiographic parameters for suspecting PH, but these may not apply to many adults with congenital heart disease (ACHD). PH is relatively common in ACHD patients and can significantly affect their exercise capacity, quality of life, and prognosis. Identification of patients who have developed PH and who may benefit from further investigations (including cardiac catheterization) and treatment is thus extremely important...
December 4, 2018: Journal of the American College of Cardiology
Jean Ferrières, Dominik Lautsch, Baishali M Ambegaonkar, Gaetano M De Ferrari, Ami Vyas, Carl A Baxter, Lori D Bash, Maja Velkovski-Rouyer, Martin Horack, Wael Almahmeed, Fu-Tien Chiang, Kian Keong Poh, Moses Elisaf, Philippe Brudi, Anselm K Gitt
BACKGROUND: Guidelines recommend lifestyle modification and medications to control risk factors in coronary heart disease (CHD). Using data from the observational DYSIS II study, we sought to evaluate the use of guideline-recommended treatments at discharge for acute coronary syndromes (ACS) or in the chronic phase for CHD, and participation in rehabilitation/secondary prevention programs. METHODS AND RESULTS: Between 2013 and 2014, 10,661 patients (3867 with ACS, 6794 with stable CHD) were enrolled in 332 primary and secondary care centers in 18 countries (Asia, Europe, Middle East)...
November 1, 2018: International Journal of Cardiology
Anton Vonk Noordegraaf, Kelly Marie Chin, François Haddad, Paul M Hassoun, Anna R Hemnes, Susan Roberta Hopkins, Steven Mark Kawut, David Langleben, Joost Lumens, Robert Naeije
The function of the right ventricle determines the fate of patients with pulmonary hypertension. Since right heart failure is the consequence of increased afterload, a full physiological description of the cardiopulmonary unit consisting of both the right ventricle and pulmonary vascular system is required to interpret clinical data correctly. Here, we provide such a description of the unit and its components, including the functional interactions between the right ventricle and its load. This physiological description is used to provide a framework for the interpretation of right heart catheterisation data as well as imaging data of the right ventricle obtained by echocardiography or magnetic resonance imaging...
December 13, 2018: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
A K Pancholia
Patients with type 2 diabetes mellitus (T2DM) exhibit an increased risk for cardiovascular (CV) events. Hyperglycemia itself contributes to the pathogenesis of atherosclerosis and heart failure (HF) in these patients, but glucose-lowering strategies studied to date have had little or no impact on reducing CV risk, especially in patients with a long duration of T2DM and prevalent CV disease (CVD). Sodium-glucose cotransporter-2 (SGLT2) inhibitors are the new class of glucose-lowering medications that increase urinary glucose excretion, thus improving glycemic control, independent of insulin...
November 2018: Indian Heart Journal
James A Hodgkinson, Richard Stevens, Sabrina Grant, Jonathan Mant, Emma P Bray, F D Richard Hobbs, Una Martin, Claire Schwartz, David McCartney, Rachel O'Mahony, Rafael Perera-Salazar, Nia Roberts, Sarah Stevens, Bryan Williams, Richard J McManus
BACKGROUND: Self-monitoring of blood pressure better predicts prognosis than clinic measurement, is popular with patients, and endorsed in hypertension guidelines. However, there is uncertainty over the optimal self-monitoring schedule. We therefore aimed to determine the optimum schedule to predict future cardiovascular events and determine "true" underlying blood pressure. METHODS: Six electronic databases were searched from November 2009 (updating a National Institute for Health and Care Excellence [NICE] systematic review) to April 2017...
January 22, 2019: American Journal of Hypertension
L K K Lee, P N W Tsai, K Y Ip, M G Irwin
Cardiac events remain the leading cause of peri-operative morbidity and mortality, and patients undergoing major surgery are exposed to significant risks which may be preventable and modifiable. Proper assessment and management of various cardiac conditions in the peri-operative period by anaesthetists can markedly improve patient safety, especially in high-risk patient populations. This involves understanding and applying current evidence-based practice and international guidelines on the main aspects of cardiac optimisation, including management of patients with hypertension, chronic heart failure, valvular heart diseases and cardiac implantable electronic devices...
January 2019: Anaesthesia
Jonathan R Skinner, Annika Winbo, Dominic Abrams, Jitendra Vohra, Arthur A Wilde
Forty per cent (40%) of sudden unexpected natural deaths in people under 35 years of age are associated with a negative autopsy, and the cardiac ion channelopathies are the prime suspects in such cases. Long QT syndrome (LQTS), Brugada syndrome (BrS) and catecholaminergic polymorphic ventricular tachycardia (CPVT) are the most commonly identified with genetic testing. The cellular action potential driving the heart cycle is shaped by a specific series of depolarising and repolarising ion currents mediated by ion channels...
October 4, 2018: Heart, Lung & Circulation
Sean M Davidson, Péter Ferdinandy, Ioanna Andreadou, Hans Erik Bøtker, Gerd Heusch, Borja Ibáñez, Michel Ovize, Rainer Schulz, Derek M Yellon, Derek J Hausenloy, David Garcia-Dorado
Many treatments have been identified that confer robust cardioprotection in experimental animal models of acute ischemia and reperfusion injury. However, translation of these cardioprotective therapies into the clinical setting of acute myocardial infarction (AMI) for patient benefit has been disappointing. One important reason might be that AMI is multifactorial, causing cardiomyocyte death via multiple mechanisms, as well as affecting other cell types, including platelets, fibroblasts, endothelial and smooth muscle cells, and immune cells...
January 8, 2019: Journal of the American College of Cardiology
Steven R Bailey, Joshua A Beckman, Timothy D Dao, Sanjay Misra, Piotr S Sobieszczyk, Christopher J White, L Samuel Wann, Steven R Bailey, Timothy Dao, Herbert D Aronow, Reza Fazel, Heather L Gornik, Bruce H Gray, Jonathan L Halperin, Alan T Hirsch, Michael R Jaff, Venkataramu Krishnamurthy, Sahil A Parikh, Amy B Reed, Fadi Shamoun, Rita E Shugart, E Kent Yucel
No abstract text is available yet for this article.
January 22, 2019: Journal of the American College of Cardiology
Antonio Pelliccia, Erik Ekker Solberg, Michael Papadakis, Paolo Emilio Adami, Alessandro Biffi, Stefano Caselli, Andrè La Gerche, Josef Niebauer, Axel Pressler, Christian M Schmied, Luis Serratosa, Martin Halle, Frank Van Buuren, Mats Borjesson, Francois Carrè, Nicole M Panhuyzen-Goedkoop, Hein Heidbuchel, Iacopo Olivotto, Domenico Corrado, Gianfranco Sinagra, Sanjay Sharma
Myocardial diseases are associated with an increased risk of potentially fatal cardiac arrhythmias and sudden cardiac death/cardiac arrest during exercise, including hypertrophic cardiomyopathy, dilated cardiomyopathy, left ventricular non-compaction, arrhythmogenic cardiomyopathy, and myo-pericarditis. Practicing cardiologists and sport physicians are required to identify high-risk individuals harbouring these cardiac diseases in a timely fashion in the setting of preparticipation screening or medical consultation and provide appropriate advice regarding the participation in competitive sport activities and/or regular exercise programmes...
December 14, 2018: European Heart Journal
Andrew J Sauer, Robert Cole, Brian C Jensen, Jay Pal, Nakul Sharma, Amin Yehya, Justin Vader
Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) that has been recommended in clinical practice guidelines to reduce morbidity and mortality in patients with chronic, symptomatic heart failure (HF) with reduced ejection fraction (HFrEF). This review provides an overview of ARNI therapy, proposes strategies to improve the implementation of sacubitril/valsartan in clinical practice, and provides clinicians with evidence-based, practical guidance on the use of sacubitril/valsartan in patients with HFrEF...
December 18, 2018: Heart Failure Reviews
Miguel Sousa-Uva, Franz-Josef Neumann, Anders Ahlsson, Fernando Alfonso, Adrian P Banning, Umberto Benedetto, Robert A Byrne, Jean-Philippe Collet, Volkmar Falk, Stuart J Head, Peter Jüni, Adnan Kastrati, Akos Koller, Steen D Kristensen, Josef Niebauer, Dimitrios J Richter, Petar M Seferovic, Dirk Sibbing, Giulio G Stefanini, Stephan Windecker, Rashmi Yadav, Michael O Zembala
No abstract text is available yet for this article.
August 27, 2018: European Journal of Cardio-thoracic Surgery
2018-11-19 16:52:03
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"